肠道微生物组与代谢物标志物在非酒精性脂肪性肝病发展中的风险评估
在社区队列2487人中随访4.6年,对90例新发非酒精性脂肪性肝病(NAFLD)与90例对照进行粪便和血清宏基因组及代谢组分析。整合基线14项微生物特征的机器学习模型分类4年随访时NAFLD状态和肝脏脂肪积累的auROC为0.72至0.80,优于其他预后临床模型的auROC 0.58至0.60。在亚洲、欧洲和美国的四个外部活检或磁共振波谱NAFLD病例对照队列中验证了微生物特征的诊断能力。
要点
- 基线肠道微生物特征模型预测4年NAFLD发展的auROC为0.72至0.80。
- 该模型优于其他预后临床模型的auROC 0.58至0.60。
- 微生物特征在四个外部NAFLD病例对照队列中验证了诊断能力。
核心结论
- 研究结果提出了利用肠道微生物群对NAFLD发展进行早期临床预警的可能性。
研究设计与样本
- 社区队列研究,纳入2487人,初始临床检查和生物样本采集后随访4.6年。
- 对90例随访时进展为NAFLD的参与者与90例保持无NAFLD的对照进行基线粪便和血清宏基因组及代谢组分析。
- 病例与对照按性别、基线及随访时体重指数(BMI)和4年BMI变化匹配。
主要发现
- 整合基线微生物特征(14项特征)的机器学习模型根据4年随访时NAFLD状态和肝脏脂肪积累正确分类参与者,auROC为0.72至0.80。
- 其他预后临床模型的auROC为0.58至0.60。
- 在亚洲、欧洲和美国的四个外部NAFLD病例对照队列(经活检或磁共振波谱检查)中测试了微生物特征的诊断能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A growing body of evidence suggests interplay between the gut microbiota and the pathogenesis of nonalcoholic fatty liver disease (NAFLD). However, the role of the gut microbiome in early detection of NAFLD is unclear. Prospective studies are necessary for identifying reliable, microbiome markers for early NAFLD. We evaluated 2487 individuals in a community-based cohort who were followed up 4.6 years after initial clinical examination and biospecimen sampling. Metagenomic and metabolomic characterizations using stool and serum samples taken at baseline were performed for 90 participants who progressed to NAFLD and 90 controls who remained NAFLD free at the follow-up visit. Cases and controls were matched for gender, age, body mass index (BMI) at baseline and follow-up, and 4-year BMI change. Machine learning models integrating baseline microbial signatures (14 features) correctly classified participants (auROCs of 0.72 to 0.80) based on their NAFLD status and liver fat accumulation at the 4-year follow up, outperforming other prognostic clinical models (auROCs of 0.58 to 0.60). We confirmed the biological relevance of the microbiome features by testing their diagnostic ability in four external NAFLD case-control cohorts examined by biopsy or magnetic resonance spectroscopy, from Asia, Europe, and the United States. Our findings raise the possibility of using gut microbiota for early clinical warning of NAFLD development.
引用
- Leung H, Long X, Ni Y, et al. Risk assessment with gut microbiome and metabolite markers in NAFLD development. Sci Transl Med. 2022. PMID: 35675435. doi:10.1126/scitranslmed.abk0855
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。